Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,015.21 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EST, Feb 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

I Predicted That ExxonMobil Would Join the $1 Trillion Club by 2030, But the Stock Is Already Up 24% in 2026. Is the High-Yield Dividend Stock Still a Buy Now? ↗

February 11, 2026

Energy stocks are in the spotlight, and ExxonMobil is best in breed.

Via The Motley Fool

Topics Artificial Intelligence

VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline ↗

February 11, 2026

The company shared optimistic timelines for advancing the clinical studies of both oral and subcutaneous VK2735 in obesity.

Via Stocktwits

Novo Nordisk Reportedly Eyes Launching Wegovy In Vials To Compete With Rival Eli Lilly ↗

February 11, 2026

Bloomberg reported on Wednesday, citing Novo CEO Mike Doustdar, that the vials are slated to be introduced in the U.S. this year.

Via Stocktwits

Topics Intellectual Property

3 Reasons to Buy Eli Lilly Stock ↗

February 11, 2026

The healthcare leader looks increasingly unstoppable.

Via The Motley Fool

Topics Government

Disney Has Its Next CEO ↗

February 11, 2026

Disney has hired a new CEO, with Josh D'Amaro taking over for Bob Iger in March.

Via The Motley Fool

Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip. ↗

February 11, 2026

Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two high-yield healthcare stocks.

Via The Motley Fool

Biotech Beat Nvidia in 2025. Can It Do It Again? ↗

February 11, 2026

Big pharma and biotech take the earnings stage with reports from Eli Lilly and Novo Nordisk leading the lineup. Will they help the industry once again outperform AI champ Nvidia?

Via The Motley Fool

Topics Artificial Intelligence

Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss

February 11, 2026

As of February 11, 2026, Incyte Corporation (NASDAQ: INCY) finds itself at a pivotal crossroads. Known for over a decade as a one-drug powerhouse centered on the hematology blockbuster Jakafi, the...

Via Finterra

Topics Economy Intellectual Property

Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore ↗

February 11, 2026

This stock has been known to soar after good news.

Via The Motley Fool

The Top 5 Analyst Questions From Eli Lilly’s Q4 Earnings Call

February 11, 2026

Eli Lilly's fourth quarter performance was defined by accelerating demand for its obesity and diabetes medicines, as well as rapid uptake in international markets. Management highlighted the strong...

Via StockStory

Topics Earnings

Zoetis (ZTS) Reports Q4: Everything You Need To Know Ahead Of Earnings

February 10, 2026

Animal health company Zoetis (NYSE:ZTS) will be announcing earnings results this Thursday morning. Here’s what to expect.

Via StockStory

Topics Artificial Intelligence

Organon Earnings: What To Look For From OGN

February 10, 2026

Pharmaceutical company Organon (NYSE:OGN) will be announcing earnings results this Thursday morning. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence World Trade

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗

February 10, 2026

Could these two companies be biotech giants in the making?

Via The Motley Fool

2 Vanguard ETFs That Could Turn $400 Per Month Into $1 Million ↗

February 10, 2026

These exchange-traded funds invest in some of the best growth stocks in the world.

Via The Motley Fool

Topics ETFs

Thinking About Investing in GLP-1 Stocks? Here Are 3 Things You Need to Know ↗

February 10, 2026

The GLP-1 market is a massive opportunity in healthcare, and many companies are vying for a piece of it.

Via The Motley Fool

AstraZeneca Signals a New Era in Obesity Care: Earnings Report Teases Oral GLP-1 Powerhouse

February 10, 2026

On February 10, 2026, AstraZeneca (NYSE:AZN) delivered an earnings report that did more than just recap a successful fiscal year; it laid down a definitive challenge to the current titans of the...

Via MarketMinute

Topics Artificial Intelligence Earnings Economy

The $80 Billion Ambition: An In-Depth Analysis of AstraZeneca (AZN) in 2026

February 10, 2026

Date: February 10, 2026 Introduction AstraZeneca PLC (NASDAQ: AZN; LSE: AZN) stands today at a critical crossroads of pharmaceutical history. Long recognized as the crown jewel of British...

Via Finterra

Topics Artificial Intelligence Economy Fraud

Hoth Therapeutics's GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial ↗

February 10, 2026

The company announced positive preclinical results from a study evaluating GDNF as a potential treatment for obesity and metabolic-associated steatotic liver disease.

Via Stocktwits

The Vertical Integration of Wellness: A Deep Dive into Hims & Hers Health (HIMS)

February 10, 2026

Today is February 10, 2026. The telehealth landscape stands at a historic inflection point, and no company better embodies this volatility than Hims & Hers Health, Inc. (NYSE: HIMS). After a meteoric...

Via Finterra

Topics Artificial Intelligence Intellectual Property Lawsuit

Eli Lilly Is Partnering with Gene-Editing Start-up Seamless Therapeutics. Here's What Investors Need to Know. ↗

February 10, 2026

Eli Lilly is flying high thanks to its success in the GLP-1 space, but what comes next?

Via The Motley Fool

Topics Intellectual Property

Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains? ↗

February 10, 2026

The stock has climbed in the triple digits over the past three years.

Via The Motley Fool

What To Expect From Royalty Pharma’s (RPRX) Q4 Earnings

February 09, 2026

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting results this Wednesday morning. Here’s what to expect.

Via StockStory

Topics World Trade

Novo Nordisk vs. Eli Lilly: What's the Better Long-Term Investment? ↗

February 09, 2026

These stocks have been going in opposite directions of late, but that doesn't mean that trend will continue.

Via The Motley Fool

Topics Intellectual Property

Over 60% of Eli Lilly's Revenue Comes From Its GLP-1 Drugs. Should Investors Be Worried? ↗

February 09, 2026

Mounjaro and Zepbound generated a combined $11.7 billion in sales for the company in its most recent quarter.

Via The Motley Fool

The GLP-1 Gold Rush Hits a Wall: Novo Nordisk Sues Hims & Hers as FDA Crackdown Triggers 20% Stock Crash

February 09, 2026

The multi-billion dollar weight-loss drug market experienced a seismic shift this morning as the era of easy-access compounded alternatives faced its most significant legal and regulatory challenge to...

Via MarketMinute

Topics Intellectual Property Lawsuit

Why Eli Lilly Stock Just Popped ↗

February 09, 2026

Novo Nordisk just did Eli Lilly stock a huge favor.

Via The Motley Fool

Topics Lawsuit

Grounded in Reality or Echoes of '99? Merrill Strategists Say Today’s S&P 500 Is a Different Beast

February 09, 2026

As the S&P 500 (INDEXSP: .INX) pushes toward the 7,100 mark in early 2026, a growing chorus of investors is nervously glancing back at the ghosts of 1999. With the index having notched double-digit...

Via MarketMinute

Topics Artificial Intelligence Lawsuit Stocks

The GLP-1 Gold Rush Hits a Wall: Hims & Hers Shares Crater After Abrupt Oral Wegovy U-Turn

February 09, 2026

The meteoric rise of telehealth giant Hims & Hers Health (NYSE: HIMS) faced its most severe reckoning this week, as the company’s stock plummeted to a one-year low following a dramatic withdrawal of...

Via MarketMinute

Topics Earnings Intellectual Property

The GLP-1 Reckoning: Why Hims & Hers (HIMS) Pivoted and Shed 20% of Its Value

February 09, 2026

On February 9, 2026, the telehealth landscape faces a reckoning. Hims & Hers Health (NYSE: HIMS), a company that once seemed invincible during the weight-loss drug gold rush of 2025, is currently...

Via Finterra

Topics Earnings Economy Intellectual Property

Eli Lilly Bets $2.4 Billion On Small Biotech To Boost Future Cell Treatments ↗

February 09, 2026

Eli Lilly shares rise after announcing a $2.4 billion deal to buy Orna Therapeutics, strengthening its push into genetic medicine despite mixed markets.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Eli Lilly (NY:LLY)

Headline News about Eli Lilly

Starting at $3.75/week.

Subscribe Today